Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo Biopharma Group plc (MREO) is a clinical-stage biopharmaceutical leader developing innovative treatments for rare diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical progress, strategic partnerships, and regulatory developments.
Our curated collection features official press releases and verified news covering critical milestones including clinical trial results, regulatory submissions, and strategic collaborations. Track updates across Mereo's pipeline targeting conditions like osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.
All content undergoes rigorous verification to ensure accuracy and relevance. For comprehensive tracking of Mereo's progress in rare disease therapeutics, bookmark this page for direct access to primary source materials and expert analysis of corporate developments.
Mereo BioPharma (NASDAQ: MREO) reported interim efficacy data from its ACTIVATE study of etigilimab, an anti-TIGIT antibody, in combination with nivolumab for advanced solid tumors. Among 15 patients evaluated, one complete response was observed in cervical cancer, one partial response in ovarian cancer, and four cases of stable disease. The study demonstrated a favorable safety profile, with no new safety signals. The trial aims to enroll around 125 patients. Further updates are anticipated in 2022.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will present at two investor conferences. The Jefferies London Healthcare Conference features an in-person fireside chat on November 17 at 10:00 a.m. GMT. The Piper Sandler 33rd Annual Virtual Healthcare Conference will have an on-demand presentation available starting November 22 at 10:00 a.m. ET. Both sessions can be accessed via the Investors section of Mereo's website, with replays available for two weeks. Mereo focuses on oncology and rare diseases, with several clinical-stage product candidates.
Mereo BioPharma Group (NASDAQ: MREO) announced the upcoming presentation of data from a study on alvelestat for treating Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting from December 11-14, 2021. The study involved seven BOS patients post-hematopoietic stem cell transplantation, revealing that alvelestat consistently suppressed biomarkers of elastase activity and collagen turnover in six patients. This indicates a potential impact on progressive lung fibrosis. The poster presentation will happen on December 11, 2021, featuring results that highlight the drug’s therapeutic promise.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that the FDA granted Orphan Drug Designation to alvelestat for treating alpha-1 antitrypsin deficiency (AATD). This designation highlights the urgent need for therapies addressing this rare, life-threatening condition. Alvelestat, currently in a Phase 2 clinical trial, aims to protect patients from lung damage caused by neutrophil elastase. The Orphan Drug Designation offers various incentives, including seven-year market exclusivity upon approval. Mereo plans to update its program by year-end 2021.
Mereo BioPharma (MREO) presented secondary endpoint data from the Phase 2b ASTEROID study for UX143 (setrusumab) at the ASBMR 2021 Annual Meeting. The study revealed a statistically significant bone-building effect in Osteogenesis Imperfecta (OI) patients, with an 8.97% increase in lumbar spine bone mineral density at 12 months in the highest dose cohort. Improvements in bone strength at the wrist and tibia were also observed. Following these results, Mereo BioPharma and Ultragenyx plan to advance UX143 into late-stage development for various OI subtypes.
Mereo BioPharma Group plc (NASDAQ: MREO) has appointed Pierre Jacquet, M.D., Ph.D. to its Board of Directors as of September 20, 2021. Dr. Jacquet brings over 20 years of experience in life sciences and strategy, previously serving as Managing Director at L.E.K. Consulting. His expertise is expected to enhance the company's clinical portfolio development. Concurrently, Peter Bains has retired from the Board after over six years of service. Mereo focuses on innovative therapies for oncology and rare diseases, with product candidates in various stages of clinical trials.
Mereo BioPharma Group plc (NASDAQ: MREO) announced participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference (Sept 13-14), SVB Leerink CybeRx Series (Sept 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 30 at 9:30am ET). A live audio webcast of the fireside chat at the Cantor Fitzgerald event will be available on the Company’s website. Mereo is focused on developing innovative therapeutics for oncology and rare diseases, with notable advances in clinical trials.
Infinity Pharmaceuticals announces the appointment of Robert Ilaria, Jr. as Chief Medical Officer, leading the clinical development of eganelisib, an oral immuno-oncology therapeutic. Ilaria brings extensive oncology experience, notably from his roles at Bristol Myers Squibb and Celgene. Brian Schwartz, previously Consulting Chief Physician, transitions to the Board of Directors. The press release highlights the promising data from ongoing studies, particularly in treating bladder and triple negative breast cancers, with plans for future development and registration studies.
Mereo BioPharma (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will speak at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 9:30 AM ET. A live audio webcast will be available on the Company’s website, with a replay accessible for two weeks.
Mereo focuses on developing therapeutics for oncology and rare diseases, with key products including etigilimab for various tumors and alvelestat for Alpha-1 antitrypsin deficiency. The Company aims to deliver improved health outcomes in these areas.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
